与每日一次的基础胰岛素相比，每周一次的伊科达克胰岛素提高了 2 型糖尿病患者的治疗满意度：对 ONWARDS 2 和 5 的患者报告结果和参与者访谈以及 ONWARDS 1 的医生调查进行分析。

IF 6.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2024-10-04 DOI:10.1016/j.diabres.2024.111885

William Polonsky , Malik Benamar , Lisbeth Carstensen , Melanie Davies , Anders Meller Donatsky , Edward Franek , Monika Kellerer , Athena Philis-Tsimikas , Ronald Goldenberg

{"title":"与每日一次的基础胰岛素相比，每周一次的伊科达克胰岛素提高了 2 型糖尿病患者的治疗满意度：对 ONWARDS 2 和 5 的患者报告结果和参与者访谈以及 ONWARDS 1 的医生调查进行分析。","authors":"William Polonsky , Malik Benamar , Lisbeth Carstensen , Melanie Davies , Anders Meller Donatsky , Edward Franek , Monika Kellerer , Athena Philis-Tsimikas , Ronald Goldenberg","doi":"10.1016/j.diabres.2024.111885","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>The ONWARDS phase 3a clinical trials evaluated once-weekly insulin icodec (icodec) versus once-daily basal insulin in type 2 diabetes. This analysis investigated the treatment-related experiences of participants from ONWARDS 5 and 2, and physicians from ONWARDS 1.</div></div><div><h3>Methods</h3><div>Patient-reported outcomes were only collected during ONWARDS 5 (icodec with a dosing guide app vs. once-daily basal analogues) and 2 (icodec vs. once-daily insulin degludec). ONWARDS 1 (icodec vs. once-daily insulin glargine U100) physicians’ treatment preferences and satisfaction were obtained via an online survey.</div></div><div><h3>Results</h3><div>In ONWARDS 5 and 2, there was a statistically significantly greater increase in total treatment satisfaction from baseline to end of treatment for icodec/icodec with app versus once-daily comparators, mostly driven by participants’ willingness to continue and recommend treatment. In ONWARDS 2, 93.7 % of icodec users preferred once-weekly over once-daily basal insulin, mainly owing to less frequent injections and ease of use. ONWARDS 1 physicians reported greater satisfaction with once-weekly than with once-daily basal insulin and were more likely to recommend once-weekly injections.</div></div><div><h3>Conclusions</h3><div>These results demonstrate improved treatment satisfaction with, and strong preferences for, once-weekly versus once-daily basal insulin. Treatment convenience and willingness to continue and recommend once-weekly basal insulin treatment were highlighted.</div><div><strong><em>Clinical trial registrations</em></strong><em>:</em> ONWARDS 1: NCT04460885; ONWARDS 2: NCT04770532; ONWARDS 5: NCT04760626</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"217 ","pages":"Article 111885"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1\",\"authors\":\"William Polonsky , Malik Benamar , Lisbeth Carstensen , Melanie Davies , Anders Meller Donatsky , Edward Franek , Monika Kellerer , Athena Philis-Tsimikas , Ronald Goldenberg\",\"doi\":\"10.1016/j.diabres.2024.111885\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aims</h3><div>The ONWARDS phase 3a clinical trials evaluated once-weekly insulin icodec (icodec) versus once-daily basal insulin in type 2 diabetes. This analysis investigated the treatment-related experiences of participants from ONWARDS 5 and 2, and physicians from ONWARDS 1.</div></div><div><h3>Methods</h3><div>Patient-reported outcomes were only collected during ONWARDS 5 (icodec with a dosing guide app vs. once-daily basal analogues) and 2 (icodec vs. once-daily insulin degludec). ONWARDS 1 (icodec vs. once-daily insulin glargine U100) physicians’ treatment preferences and satisfaction were obtained via an online survey.</div></div><div><h3>Results</h3><div>In ONWARDS 5 and 2, there was a statistically significantly greater increase in total treatment satisfaction from baseline to end of treatment for icodec/icodec with app versus once-daily comparators, mostly driven by participants’ willingness to continue and recommend treatment. In ONWARDS 2, 93.7 % of icodec users preferred once-weekly over once-daily basal insulin, mainly owing to less frequent injections and ease of use. ONWARDS 1 physicians reported greater satisfaction with once-weekly than with once-daily basal insulin and were more likely to recommend once-weekly injections.</div></div><div><h3>Conclusions</h3><div>These results demonstrate improved treatment satisfaction with, and strong preferences for, once-weekly versus once-daily basal insulin. Treatment convenience and willingness to continue and recommend once-weekly basal insulin treatment were highlighted.</div><div><strong><em>Clinical trial registrations</em></strong><em>:</em> ONWARDS 1: NCT04460885; ONWARDS 2: NCT04770532; ONWARDS 5: NCT04760626</div></div>\",\"PeriodicalId\":11249,\"journal\":{\"name\":\"Diabetes research and clinical practice\",\"volume\":\"217 \",\"pages\":\"Article 111885\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes research and clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168822724007952\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822724007952","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的：ONWARDS 3a 期临床试验评估了每周一次胰岛素 icodec（icodec）与每日一次基础胰岛素治疗 2 型糖尿病的效果。本分析调查了 ONWARDS 5 和 2 试验参与者以及 ONWARDS 1 试验医生的治疗相关经验：仅在 ONWARDS 5（带剂量指南应用程序的 icodec 与每日一次的基础类似物相比）和 ONWARDS 2（icodec 与每日一次的德谷胰岛素相比）期间收集了患者报告的结果。通过在线调查了解了ONWARDS 1（icodec与每日一次的格列奈胰岛素U100对比）中医生的治疗偏好和满意度：在 ONWARDS 5 和 2 中，从基线到治疗结束，icodec/icodec 与每日一次的比较药相比，icodec 的总治疗满意度在统计学上有显著提高，这主要是由于参与者愿意继续治疗并推荐治疗。在 ONWARDS 2 中，93.7% 的 icodec 使用者更喜欢每周一次的基础胰岛素，而不是每日一次的基础胰岛素，主要原因是注射次数少和使用方便。ONWARDS 1 的医生对每周一次基础胰岛素的满意度高于每日一次基础胰岛素，并且更倾向于推荐每周一次注射：这些结果表明，与每日一次的基础胰岛素相比，每周一次的基础胰岛素治疗满意度更高，且更受青睐。临床试验注册：临床试验注册：NCT04460885；NCT04770532；NCT04760626：NCT04760626。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1

Aims

The ONWARDS phase 3a clinical trials evaluated once-weekly insulin icodec (icodec) versus once-daily basal insulin in type 2 diabetes. This analysis investigated the treatment-related experiences of participants from ONWARDS 5 and 2, and physicians from ONWARDS 1.

Methods

Patient-reported outcomes were only collected during ONWARDS 5 (icodec with a dosing guide app vs. once-daily basal analogues) and 2 (icodec vs. once-daily insulin degludec). ONWARDS 1 (icodec vs. once-daily insulin glargine U100) physicians’ treatment preferences and satisfaction were obtained via an online survey.

Results

In ONWARDS 5 and 2, there was a statistically significantly greater increase in total treatment satisfaction from baseline to end of treatment for icodec/icodec with app versus once-daily comparators, mostly driven by participants’ willingness to continue and recommend treatment. In ONWARDS 2, 93.7 % of icodec users preferred once-weekly over once-daily basal insulin, mainly owing to less frequent injections and ease of use. ONWARDS 1 physicians reported greater satisfaction with once-weekly than with once-daily basal insulin and were more likely to recommend once-weekly injections.

Conclusions

These results demonstrate improved treatment satisfaction with, and strong preferences for, once-weekly versus once-daily basal insulin. Treatment convenience and willingness to continue and recommend once-weekly basal insulin treatment were highlighted.

Clinical trial registrations: ONWARDS 1: NCT04460885; ONWARDS 2: NCT04770532; ONWARDS 5: NCT04760626

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.